These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 38842929)

  • 1. Trust but Verify: Lessons Learned for the Application of AI to Case-Based Clinical Decision-Making From Postmarketing Drug Safety Assessment at the US Food and Drug Administration.
    Ball R; Talal AH; Dang O; Muñoz M; Markatou M
    J Med Internet Res; 2024 Jun; 26():e50274. PubMed ID: 38842929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time?
    Ball R; Dal Pan G
    Drug Saf; 2022 May; 45(5):429-438. PubMed ID: 35579808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation.
    Mockute R; Desai S; Perera S; Assuncao B; Danysz K; Tetarenko N; Gaddam D; Abatemarco D; Widdowson M; Beauchamp S; Cicirello S; Mingle E
    Pharmaceut Med; 2019 Apr; 33(2):109-120. PubMed ID: 31933254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feature engineering and machine learning for causality assessment in pharmacovigilance: Lessons learned from application to the FDA Adverse Event Reporting System.
    Kreimeyer K; Dang O; Spiker J; Muñoz MA; Rosner G; Ball R; Botsis T
    Comput Biol Med; 2021 Aug; 135():104517. PubMed ID: 34130003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Machine Learning Approach with Human-AI Collaboration for Automated Classification of Patient Safety Event Reports: Algorithm Development and Validation Study.
    Chen H; Cohen E; Wilson D; Alfred M
    JMIR Hum Factors; 2024 Jan; 11():e53378. PubMed ID: 38271086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Interoperable Computable Phenotype Algorithms for Adverse Events of Special Interest to Be Used for Biologics Safety Surveillance: Validation Study.
    Holdefer AA; Pizarro J; Saunders-Hastings P; Beers J; Sang A; Hettinger AZ; Blumenthal J; Martinez E; Jones LD; Deady M; Ezzeldin H; Anderson SA
    JMIR Public Health Surveill; 2024 Jul; 10():e49811. PubMed ID: 39008361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a natural language processing algorithm using national reporting data to improve identification of anesthesia-related ADVerse evENTs: The "ADVENTURE" study.
    Mertes PM; Morgand C; Barach P; Jurkolow G; Assmann KE; Dufetelle E; Susplugas V; Alauddin B; Yavordios PG; Tourres J; Dumeix JM; Capdevila X
    Anaesth Crit Care Pain Med; 2024 Aug; 43(4):101390. PubMed ID: 38718923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
    Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
    Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial Intelligence for Drug Toxicity and Safety.
    Basile AO; Yahi A; Tatonetti NP
    Trends Pharmacol Sci; 2019 Sep; 40(9):624-635. PubMed ID: 31383376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting.
    Schotland P; Racz R; Jackson DB; Soldatos TG; Levin R; Strauss DG; Burkhart K
    Clin Pharmacol Ther; 2021 May; 109(5):1232-1243. PubMed ID: 33090463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing drug safety of hepatitis C therapies using post-market data.
    Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
    BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theory of trust and acceptance of artificial intelligence technology (TrAAIT): An instrument to assess clinician trust and acceptance of artificial intelligence.
    Stevens AF; Stetson P
    J Biomed Inform; 2023 Dec; 148():104550. PubMed ID: 37981107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing an Artificial Intelligence-Guided Signal Detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A Proof-of-Concept Study Using Galcanezumab and Simulated Data.
    Al-Azzawi F; Mahmoud I; Haguinet F; Bate A; Sessa M
    Drug Saf; 2023 Aug; 46(8):743-751. PubMed ID: 37300636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward a responsible future: recommendations for AI-enabled clinical decision support.
    Labkoff S; Oladimeji B; Kannry J; Solomonides A; Leftwich R; Koski E; Joseph AL; Lopez-Gonzalez M; Fleisher LA; Nolen K; Dutta S; Levy DR; Price A; Barr PJ; Hron JD; Lin B; Srivastava G; Pastor N; Luque US; Bui TTT; Singh R; Williams T; Weiner MG; Naumann T; Sittig DF; Jackson GP; Quintana Y
    J Am Med Inform Assoc; 2024 Nov; 31(11):2730-2739. PubMed ID: 39325508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial Intelligence and the Future of the Drug Safety Professional.
    Danysz K; Cicirello S; Mingle E; Assuncao B; Tetarenko N; Mockute R; Abatemarco D; Widdowson M; Desai S
    Drug Saf; 2019 Apr; 42(4):491-497. PubMed ID: 30343417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.